Mesoblast Limited (MESO)
NASDAQ: MESO
· Real-Time Price · USD
15.86
-0.45 (-2.76%)
At close: Sep 26, 2025, 3:59 PM
15.86
0.00%
After-hours: Sep 26, 2025, 04:10 PM EDT
-2.76% (1D)
| Bid | 15.81 |
| Market Cap | 1.95B |
| Revenue (ttm) | 5.67M |
| Net Income (ttm) | -103.35M |
| EPS (ttm) | -0.85 |
| PE Ratio (ttm) | -18.66 |
| Forward PE | -49.42 |
| Analyst | Hold |
| Dividends | n/a |
| Ask | 17.14 |
| Volume | 124,201 |
| Avg. Volume (20D) | 261,006 |
| Open | 15.80 |
| Previous Close | 16.31 |
| Day's Range | 15.60 - 15.99 |
| 52-Week Range | 7.09 - 22.00 |
| Beta | 1.17 |
| Ex-Dividend Date | n/a |
About MESO
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol MESO
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for MESO stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsMesoblast Limited is scheduled to release its earnings on
Feb 25, 2026,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 week ago
+4.32%
Mesoblast shares are trading higher after the comp...
Unlock content with
Pro Subscription
1 month ago
-13.29%
Mesoblast shares are trading lower after the company reported worse-than-expected FY EPS results.
2 months ago · https://www.proactiveinvestors.com
Mesoblast shares surge on strong Ryoncil launch, tapering off after Friday rallyShares in Mesoblast Ltd (NASDAQ:MESO, ASX:MSB) surged by nearly 38% following Friday’s successful commercial launch of its FDA-approved treatment, Ryoncil®, for steroid-refractory acute graft-versus-h...
